Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

QuantaLife

Explore full profile

Products and services for the life science research and clinical diagnostic markets

Pleasanton, United StatesFounded 2008Biotechnology
Valuation $100–250M Last recorded · 2011
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for QuantaLife and the history behind them.

About QuantaLife

QuantaLife, a subsidiary of Bio-Rad Laboratories, specializes in developing advanced multiplex immunoassay systems that enable the detection and quantification of multiple biomarkers, such as proteins, peptides, and nucleic acids, within a single sample. These systems are integral to life science research, clinical diagnostics, and biopharmaceutical processing. QuantaLife's core product, the Bio-Plex Multiplex Immunoassay System, includes instruments, software, calibration and validation tools, and multiplex assay kits, providing a comprehensive solution for high-throughput analysis. The company serves a diverse clientele, including university and research institutions, hospitals, public health and commercial laboratories, as well as biotechnology and pharmaceutical companies. Operating in the life sciences and healthcare markets, QuantaLife generates revenue through the sale of its sophisticated assay systems and related consumables, as well as through service contracts and support.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2008
Headquarters
Pleasanton, United States
Open positions
None listed
Dealroom signal
18.7/100
Sector
Biotechnology
Client focus
b2b

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Oct 2011 $162M $162M Bio-Rad Laboratories —
DEBT✓Debt Jul 2011 $3.6M — Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

QuantaLife website traffic

Latest recorded traffic for QuantaLife is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Paladin Capital Group

Other known investors2 additional known investors

  • Bio-Rad Laboratories
  • Mérieux Equity Partners
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Pleasanton HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about QuantaLife on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See QuantaLife’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.